CellCentric has kicked off dosing of its first registration-supporting study for the oral p300/CBP inhibitor inobrodib in multiple myeloma today
Solid Biosciences CEO Bo Cumo discusses recent DMD data for the company's microdystrophin gene therapy, and explains the development and regulatory steps ahead
Christian Tidona's BioMed X and Michal Preminger are launching BioMed X Venture Labs in Cambridge, MA to create 'build to solve' startups with partners



BiotechTV - News